CV Lattes
ORCID
Google Scholar Citations
Centro Infantil de Investigações Hematológicas Dr Domingos A Boldrini (CIB) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Dr Yunes received his PhD in genetics by the State University of Campinas, in 1997, Seven month later he was recruited by the Boldrini Children's Hospital to start a Molecular Biology Laboratory. From 2001 to 2003 he completed his postdoctoral training at the Dana-Farber Cancer Institute, Harvard Medical School. Currently, Dr Yunes is head of the molecular biology laboratory, at Boldrini, and holds secondary appointments in Genetics at the State University of Campinas. His research work is mainly focused on elucidating the genetic and molecular mechanisms of leukemia progression and resistance to therapy. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
The enzyme L-asparaginase II is one of the drugs of choice for the polychemotherapeutic treatment of Acute Lymphoblastic Leukemia (ALL) in children and adults. Despite being a rare disease, ALL is the most common cancer in children and accounts for 25% of all cancers in children up to 15 years of age. Commonly, neoplastic cells use plasma asparagine for the synthesis of proteins. Asparagi…
Currently, the Boldrini Research Center(BRC)team consists of 11 (eleven) doctors and approximately 25 technicians and graduate/undergraduate students (doctorate, master or scientific initiation). Four main projects are underway: (i) analysis of minimal residual disease in acute lymphoblastic leukemia, (ii) study of leukemogenesis using an animal model of floxed IL7R mutant, (iii) producti…
Cellular microtubules are anticancer targets extensively validated in the clinic. Anti-tubulin agents that interact with the colchicine binding site are attracting a lot of interest for development of new drugs against cancer. We have designed, synthesized and tested a series of colchicine analogues and assessed their potential as anti-cancer agents. Compounds obtained showed in vitro ant…
(Only some records are available in English at this moment)
Acute lymphoid leukemia (ALL) is the main cancer affecting children. Despite the high cure rates achieved in recent decades, and even with great effort in the search for new therapeutic strategies, approximately 20 to 30% of cases relapse from the disease, due to resistance to chemotherapy. Although some genetic subgroups of ALL are associated with a peculiar drug resistance/sensitivity p…
Acute Lymphoid Leukemia (ALL) is the most common type of pediatric cancer, being subclassified into B-cell ALL and T-cell ALL (T-ALL). T-ALL is an aggressive neoplasm, responsible for 15% of pediatric ALL cases, and is characterized by the abnormal proliferation of cells similar to T lymphocyte progenitors, which, due to an accumulation of molecular changes, have their maturation cycle in…
Acute lymphoid leukemia (ALL) is a pathology that affects cells of the lymphoid lineage, and its cases can be classified as T-cell or B-cell ALL. Different factors are related to the leukemogenesis process of ALL, which can be induced by an abnormal immune response to common infections, lack of cell competition, fusions resulting from chromosomal rearrangements and lesions in transcriptio…
(Only some records are available in English at this moment)
Acute lymphoblastic leukemia (ALL) represents the most common type of cancer in childhood, accounting for a quarter of all childhood malignancies. Although approximately 80% of patients are cured, the main cause of treatment failure is resistance to drugs used during treatment. Methotrexate (MTX) is one of the main drugs used to combat ALL, as it inhibits nucleotide synthesis and induces …
Leukemias are hematologic neoplastic diseases, which are characterized by the uncontrolled proliferation of hematopoietic cells and are classified according to the phenotype of the affected cell. In this study, we will focus on acute promyelocytic leukemia (APL), belonging to the group of acute myeloid leukemia (AML), subgroup M3 or M3 variant. LPA is characterized by a t(15;17) chromosom…
Leukemia is a malignant disease characterized by uncontrolled proliferation and interruption of the development of leukocyte precursors in the bone marrow. In this project, the Acute Lymphoid Leukemia (ALL) and Chronic Myeloid Leukemia (CML) carrying the translocation t(9; 22) will be studied [BCR-ABL1], which results in the Philadelphia chromosome that is related to high rates of recurre…
(Only some records are available in English at this moment)
Acute Promyelocytic Leukemia (APL) is characterized by presence of the chromosomal translocation t(15;17) which generates the PML RARA fusion protein. All-trans retinoic acid (ATRA) is one of the main components used for APL treatment. Mutations in the ligand-binding domain (LBD) of the fused RARa nuclear receptor have been associated to ATRA resistance. We sequenced diagnostic and relaps…
Insulin and insulin-like growth factors (IGFs) are mitogenic and pro-survival factors to many different cell types. Circulating IGFs are bound by IGF binding proteins (IGFBPs) that regulate their action. IGFBP7 is a novel IGFBP-related protein (IGFBP-rP) that, in contrast to other IGFBPs/IGFBP-rPs, features higher affinity for insulin than for IGFs. We previously demonstrated that IGFBP7 …
The oncogenic IL7R is known to activate three pathways in acute lymphoid leukemia (ALL): JAK/STAT, PI3K/AKT/mTOR and RAS/MEK/ERK. However, the activation of RAS/MEK/ERK has not been characterized. Mutations in RAS/MEK/ERK are recurrent in human ALL (7/15 cases of ALL with mutations in the IL7R have cooccurring mutations in genes of the RAS/MEK/ERK pathway) and in murine ALL originating fr…
(Only some records are available in English at this moment)
| 15 / 9 | Completed research grants |
| 5 / 5 | Ongoing scholarships in Brazil |
| 40 / 29 | Completed scholarships in Brazil |
| 8 / 8 | Completed scholarships abroad |
| 68 / 51 | All research grants and scholarships |
| Associated processes | |